|
|
|||||
|
||||||
|
||||||
|
||||||
|
||||||
|
||||||
教育背景 |
||||||
北京大学理学博士(2011) |
||||||
北京大学理学硕士(2008) |
||||||
北京大学理学学士(2004) |
||||||
|
|
|||||
工作经历 |
||||||
2017至今 北京大学药学院,学生党总支书记(2017-18),党委委员(2022),院长助理(2023) |
||||||
2011至今 北京大学药学院药事管理与临床药学系,讲师(2011),副教授(2018), 硕导(2018),副主任(2018),主任(2019),PI(2020),博导(2020),研究员(2023) |
||||||
2018.9-2019.9 美国哈佛大学医学院,访问学者 |
||||||
2004.8-2005.7 青海省西宁市大通县民族完全中学,志愿教师 |
||||||
|
|
|||||
社会兼职 |
||||||
世界卫生组织药品价格政策技术咨询核心专家小组(WHO TAG-PPM)专家 (2023) |
||||||
中国医疗保健国际交流促进会循证医学分会 常务委员 秘书长(2023) |
||||||
国家药品监督管理局药品评价中心药物警戒研究与评价重点实验室 学术委员会委员(2021) |
||||||
国家卫生健康委能力建设和继续教育中心现代医院管理能力建设专家委员会药事管理分委员会 委员(2020) |
||||||
|
|
|||||
代表性论文(近一年) |
||||||
1.Hu L, Fu M, Wushouer H, Ling K, Shi L, Guan X*. Association Between β-lactam Allergy Documentation and Outpatient Antibiotic Prescribing in Primary Healthcare Facilities in China. J Hosp Infect. 2023 Sep 1:S0195-6701(23)00282-7.(SCIE, Q1, IF-2022=6.9) 2.Fu M, Gong Z, Li C, Ling K, Zhu Y, Li H, Shi L, Guan X*. Appropriate use of antibiotics for acute respiratory infections at primary healthcare facilities in China: a nationwide cross-sectional study from 2017 to 2019. Lancet Reg Health West Pac. 2023 Aug 18;40:100880.(SCIE, SSCI, Q1, IF-2022=7.1) 3.Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X*. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data. J Glob Health. 2023 Aug 11;13:04083.(SCIE, SSCI, Q1, IF-2022=7.2) 4.Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S, Denburg A, Guan X*. Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021. EClinicalMedicine. 2023 Apr 12;59:101966. (SCIE, Q1, IF-2022=15.1) 5.Wushouer H, Zhou Y, Zhang W, Hu L, Du K, Yang Y, Yao G, Little P, Zheng B, Guan X*, Shi L. Inpatient antibacterial use trends and patterns, China, 2013-2021. Bull World Health Organ. 2023 Apr 1;101(4):248-261B. (SCIE, Q1, IF-2022=11.1) 6.Zhang Y, Wagner AK, Guan X*. Newly approved cancer drugs in China - innovation and clinical benefit. Nat Rev Clin Oncol. 2023 Mar;20(3):135-136. (SCIE, Q1, IF-2022=78.8) 7.Fu M, Zhu Y, Gong Z, Li C, Li H, Shi L*, Guan X*. Benzodiazepine Receptor Agonists Prescribing for Insomnia Among Adults in Primary Health Care Facilities in Beijing, China. JAMA Netw Open. 2023 Feb 1;6(2):e230044. (SCIE, Q1, IF-2022=13.8) 8.Wushouer H, Yang Y, Deng Y, Zheng B, Shi L, Guan X*. A comparative study of antibiotic use in China under Chinese restriction list and world health Organization AWaRe classification. Clin Microbiol Infect. 2022 Dec 13:S1198-743X(22)00631-0. (SCIE, Q1, IF-2022=14.2) 9.Fu M, Gong Z, Zhu Y, Li C, Zhou Y, Hu L, Li H, Wushouer H, Guan X*, Shi L. Inappropriate antibiotic prescribing in primary healthcare facilities in China: a nationwide survey, 2017-2019. Clin Microbiol Infect. 2022 Nov 25:S1198-743X(22)00587-0. (SCIE, Q1, IF-2022=14.2) 10.Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X*. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020. JAMA Netw Open. 2022;5(8):e2225973. (SCIE, Q1, IF-2022=13.8) 11.Zhang Y, Guan X. Misleading Reporting in Statistically Not Significant Oncology Trials-Joining Efforts Toward Unbiased Results Interpretation. JAMA Netw Open. 2021 Dec 1;4(12):e2138695. (SCIE, Q1, IF-2021=13.36) 12.Naci H, Guan X, Woloshin S, Xu Z, Wagner AK. Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs. JAMA Intern Med. 2021 Nov 1;181(11):1521-1522. (SCIE, Q1, IF-2021=44.424) 13.Fu M, Naci H, Booth C, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner A. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med. 2021 Oct 18;e215983. (SCIE, Q1, IF-2021=44.424) 14.Huang T, Wagner A, Bai L, Huang C, Guan X*, Shi L. Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending. Cancer Commun (Lond). 2021 Apr;41(4):345-348.(SCIE, Q1, IF-2021=15.283) 15.贺子璇,黄先琴,陈定一,王国安,朱玥桢,韩晟,管晓东*,史录文.中国国家医保谈判药品药物经济学评价研究的系统评价 [J].中国循证医学杂志,2023,23(02):159-169. 16.杨雨,胡华杰,黄涛,巩志文,管晓东*,史录文.医务人员“共诊患者”网络研究的范围综述[J]. 中国循证医学杂志,2023,23(02):197-202. 17.保琦,胡琳,胡华杰,黄涛,傅孟元,海沙尔江·吾守尔,管晓东*,史录文.超说明书用药医疗损害责任纠纷判决与循证证据 的相关性分析[J].中国药房,2022,33(15):1810-1813+1819. |
||||||
|
||||||
荣誉奖励 |
||||||
北京大学课程思政示范课程(2022) |
||||||
北京大学教学成果二等奖(2022) |
||||||
北京市科学技术进步奖二等奖(2021) |
||||||
北京大学药学院第四届“我最喜爱的导师”称号(2020) |
||||||
第37届国际药物流行病学与治疗风险管理会议Spotlight Poster(2020) |
||||||
国际药物流行病学学会2018年会John Snow Award(2018) |
||||||
北京大学医学部教学优秀奖(2017、2018) |
||||||
北京大学青年岗位能手标兵(2017) |
||||||
北京大学优秀共产党员,北京大学优秀班主任标兵(2016) |
||||||
北京大学医学部优秀教师(2013、2015) |